In addition to offering accurate hereditary cancer test results, Myriad myRisk® includes riskScore for eligible women to provide more comprehensive breast cancer risk assessment.
riskScore provides comprehensive, personalized risk assessment for certain women for a 5-year and remaining lifetime risk of developing breast cancer, analyzing several personalized factors at no additional cost.
riskScore can provide further insight for certain women who remain high-risk without a pathogenic mutation. By incorporating over 80 well-studied and validated genetic markers with the Tyrer-Cuzick risk model, riskScore reports a 5-year and remaining lifetime risk for breast cancer. Women who receive a riskScore will have this information included in the myRisk Management Tool to assist in the development of a treatment plan.
To see who is eligible for riskScore, click here
This means that certain patients will receive more critical information to help guide your medical management plan for breast cancer prevention and early identification.
Recommend a medical management plan based on the a woman’s personal risk of breast cancer instead of a range of risk assoiciated with a pathogenic CHEK2 mutation.
riskScore has been validated in multiple studies and continues to advance the science of breast cancer risk assessment. First presented at the American Society of Clinical Oncology Meeting (ASCO) in 2017, the genetic markers used in riskScore have been peer-reviewed and published in JCO Precision Oncology.
In addition to the validation of the genetic markers used in riskScore, Myriad continues to publish studies and advance the science of breast cancer risk assessment. To review all of our published studies, visit our Publications page.
In addition to myRisk results, the myRisk Management Tool will include riskScore results and leading society guidelines for patients who may be at or above the 20% threshold for consideration of modified medical management. Your patient’s clinical history will also be included in an easy-to-read format to provide you and your patient with as much information as possible as your form a plan together.
riskScore has been validated based on previously identified genetic markers that are specific to certain populations, cancer histories, and mutation statuses.
*High-penetrance breast cancer risk genes: BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM c.7271T>G., and bi-allelic CHEK2
Myriad is on the forefront of hereditary cancer testing and breast cancer risk assessment and is working diligently towards expanding accessibility to riskScore for women of all ancestries.
If you have further questions about riskScore, contact your local Myriad Account Executive or Regional Medical Specialists or call 1-800-4-MYRIAD
Sign up to receive riskScore email udpates